TRANSVAC2, an European vaccine research and development (R&D) infrastructure project, is dedicated to accelerating the development of safe, effective and affordable vaccines.

ECRIN supports clinical trials across borders. How do we do that? We are very proud to show it to you in our brand new video!

The EU-SolidAct trial, previously authorized under the EU CT Directive 2001/20/EC, has been successfully transferred and is authorized under the new EU regulation (Regulation (EU) No 536/2014) in 12 countries.

After more than 2 years, our partner EUPATI organises the Fundamentals in a face to face session. EUPATI Fundamentals is a training about Patient Engagement addressed to professionals in academia and pharmaceutical industry.

The MACUSTAR project has received a second Letter of Support from the European Medicines Agency (EMA) for its work on new measures to assess the eye disease age-related macular degeneration in clinical trials.

EU-AMRI, the European Alliance of Medical Research Infrastructures, was officially launched during a live broadcast from Brussels on 5 April 2022.

International Clinical Trial Day 2022 will be co-hosted by ECRIN (European Clinical Research Infrastructure Network) and its German scientific partner KKS-Netzwerk (the Network of Coordinating Centres for Clinical Trials) on May 17th 2022, and this years’ theme is Recruitment in Clinical Trials.

On 17 March, the PERMIT project held its Implementation Workshop.

ISIDORe – “Integrated Services for Infectious Disease Outbreak Research” was officially launched on the 24 February 2022.

The PERMIT project hosted its 4th General Assembly on 4 February 2022. With the approval of the 6-month no-cost extension of the project, this meeting marks the beginning of the home stretch for the project. Each work package presented the actions carried out since July 2021.

In January 2022 Ecraid became a legal entity and is now fully operational to advance knowledge in the field of infectious diseases.

The European

ECRIN has engaged in a strategic bilateral partnership with EUPATI, the European Patients’ Academy on Therapeutic Innovation.

Medical device development, from conception to timely release to market, can be expensive and risky. This is particularly true for high-risk medical devices affected by the EU’s current Regulation 2017/745.

This policy brief, entitled ” Scaling-Up Research Projects Through ERICs: Impact of Big Science on The Research Ecosystem” showcases the pivotal role of Research Infrastructures (RIs) and ERICs in particular in the European research development and innovation ecos

The International Rare Diseases Research Consortium (IRDiRC) is proud to announce the publication of a commentary on 10 years of progress and challenges of IRDiRC in the prestigious journal Nature Reviews Drug Discovery.

The Joint Access Advisory Mechanism (JAAM) is the entryway for the European COVID-19 adaptive platform trials (APTs).

On January 19^th, the ECRAID Prime project held its official kick-off meeting online. This ambitious project aims to establish a network for the implementation of an early phase platform trial for COVID-19 treatments in the primary care setting.

F-CRIN, ECRIN’s French national scientific partner, certified 4 new research and investigation networks on pathologies of national interest: